The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use - Eiermann, W; Rezai, M; Kümmel, S (Ann Oncol, 2013)
et al.